The Endocrine Society
The latest news from the ENDO Annual Meeting, with physician perspective, researcher interviews and clinician insight on diabetes, thyroid and other endocrine disorders.
Related Articles
FDA grants orphan drug designation to taladegib for IPF
The FDA granted an orphan drug designation to novel hedgehog pathway inhibitor taladegib, also known as ENV-101, for treating patients with idiopathic pulmonary fibrosis, according…
Why taxes matter when choosing where to retire
When planning for retirement, many people consider relocation to a different state from the one where they have spent their preretirement years.
What’s Next? | Journals Gateway | American Diabetes Association
The future of diabetes care is evolving—Are you ready for what’s next? What’s Next? is an exclusive limited-series podcast that takes you inside the latest…
Phase 2 trial: Preservative-free eye drop promising for vascularized pinguecula, hyperemia
Cloudbreak Pharma reported positive topline results from a phase 2 clinical trial that assessed a preservative-free ophthalmic solution for the treatment of vascularized pinguecula and…
Academic Detailing Plus Pre-Visit Handout Improves Diabetes Deprescribing
Academic detailing plus pre-visit patient activation was associated with sustained diabetes deprescribing rates at 12 months in older adults with T2D.
Meet Incoming Endocrine Society President Carol Lange, PhD – Endocrine News
The Endocrine Society is pleased to welcome Carol Lange, PhD, who takes office during ENDO 2025 in San Francisco. Lange succeeds John Newell-Price, MD, PhD,…
Q&A: What are new complicated UTI guidelines?
For the first time in more than a decade, the Infectious Diseases Society of America updated its guidelines for complicated urinary tract infections.
FDA rejects RP1 for advanced melanoma, says IGNYTE not a ‘well-controlled’ trial
The FDA has issued a complete response letter to Replimune indicating it is unable to approve the biologics license application for vusolimogene oderparepvec in combination…
Linzagolix Sustains Reduced Menstrual Bleeding in Uterine Fibroids at 1 Year
Linzagolix therapy was associated with significantly reduced heavy menstrual bleeding by week 52 among patients with uterine fibroids.
VIDEO: Company sets sights on making precision medicine ‘as personal as a fingerprint’
A functional precision medicine platform intends to streamline cancer treatment by matching patients against a battery of FDA-approved drugs to deliver an individualized treatment plan…